Testing effectiveness (Phase 2)Study completedNCT00003673What this trial is testingCMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First RelapseWho this might be right forLeukemia Pfizer 55
Testing effectiveness (Phase 2)Active Not RecruitingNCT05029141What this trial is testingNew Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaWho this might be right forAcute Myeloid LeukemiaRefractory Acute LeukemiaRelapsed Adult AML The First Affiliated Hospital of Soochow University 21
Early research (Phase 1)Study completedNCT00258271What this trial is testingCladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous LeukemiaWho this might be right forLeukemia University of Rochester 18
Early research (Phase 1)Not Yet RecruitingNCT07432100What this trial is testingClinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid LeukemiaWho this might be right forAcute Myeloid LeukemiaChimeric Antigen Receptor T-cellUniversal CLL1 CAR-T Mingfeng Zhao 20
Early research (Phase 1)Study completedNCT00022451What this trial is testingTipifarnib in Treating Young Patients With Refractory LeukemiaWho this might be right forLeukemia National Institutes of Health Clinical Center (CC)
Testing effectiveness (Phase 2)Ended earlyNCT00939653What this trial is testingT2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)Who this might be right forRelapsed Acute Myelogenous Leukemia Therapeutic Advances in Childhood Leukemia Consortium 6
Early research (Phase 1)Ended earlyNCT02267863What this trial is testingAPTO-253 in Patients With Relapsed or Refractory AML or MDSWho this might be right forAcute Myelogenous Leukemia in RelapseAcute Myelogenous Leukemia, Relapsed, AdultAcute Myelogenous Leukemia, Adult+2 more Aptose Biosciences Inc. 21
Testing effectiveness (Phase 2)UnknownNCT01039363What this trial is testingVorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid LeukemiaWho this might be right forAcute Myeloid Leukemia Samsung Medical Center 27
Testing effectiveness (Phase 2)Study completedNCT02937662What this trial is testingEfficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AMLWho this might be right forAcute Myeloid Leukemia Institute of Hematology & Blood Diseases Hospital, China 20
Early research (Phase 1)Study completedNCT00004047What this trial is testingChemotherapy in Treating Patients Who Have Hematologic CancerWho this might be right forLeukemiaMyelodysplastic Syndromes Daiichi Sankyo
Testing effectiveness (Phase 2)Study completedNCT00365287What this trial is testingCombination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney CancerWho this might be right forBreast CancerKidney CancerLeukemia+3 more Masonic Cancer Center, University of Minnesota 148
Testing effectiveness (Phase 2)Looking for participantsNCT05601726What this trial is testingFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult PatientsWho this might be right forAcute Myeloid Leukemia, AdultMyelodysplastic Syndromes Advanced BioDesign 36
Testing effectiveness (Phase 2)Looking for participantsNCT07584889What this trial is testingEfficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic MalignanciesWho this might be right forB Cell LymphomaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia Shenzhen University General Hospital 10
Testing effectiveness (Phase 2)UnknownNCT03053206What this trial is testingA Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid LeukemiaWho this might be right forAcute Myeloid Leukemia, in Relapse All India Institute of Medical Sciences 84
Testing effectiveness (Phase 2)Study completedNCT00003840What this trial is testingDTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaWho this might be right forLeukemia Wake Forest University Health Sciences
Testing effectiveness (Phase 2)Study completedNCT00006240What this trial is testingPhenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaWho this might be right forLeukemia National Heart, Lung, and Blood Institute (NHLBI)
Not applicableNo Longer AvailableNCT03409081What this trial is testingEarly Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)Who this might be right forAcute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT00798213What this trial is testingSCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)Who this might be right forLeukemia, Myeloid, AcuteLymphoblastic Leukemia, Acute Merck Sharp & Dohme LLC 29
Early research (Phase 1)Study completedNCT00012376What this trial is testingChemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)+15 more National Cancer Institute (NCI) 35
Early research (Phase 1)Study completedNCT00497991What this trial is testingSafety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid LeukemiaWho this might be right forMyeloid Leukemia AstraZeneca 65